• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Virology . Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epit

tetano

Editor, Senior Moderator
Virology


. 2021 Dec 10;566:143-152.
doi: 10.1016/j.virol.2021.12.003. Online ahead of print.
Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes


Bo Ryoung Park[SUP] 1 [/SUP], Jeeva Subbiah[SUP] 1 [/SUP], Ki-Hye Kim[SUP] 1 [/SUP], Young-Man Kwon[SUP] 1 [/SUP], Judy Oh[SUP] 1 [/SUP], Min-Chul Kim[SUP] 2 [/SUP], Chong-Hyun Shin[SUP] 1 [/SUP], Baik Lin Seong[SUP] 3 [/SUP], Sang-Moo Kang[SUP] 4 [/SUP]



Affiliations

Abstract

Annual repeat influenza vaccination raises concerns about protective efficacy against mismatched viruses. We investigated the impact of heterologous prime-boost vaccination on inducing cross protection by designing recombinant influenza viruses with chimeric hemagglutinin (HA) carrying M2 extracellular domains (M2e-HA). Heterologous prime-boost vaccination of C57BL/6 mice with M2e-HA chimeric virus more effectively induced M2e and HA stalk specific IgG antibodies correlating with cross protection than homologous prime-boost vaccination. Induction of M2e and HA stalk specific IgG antibodies was compromised in 1-year old mice, indicating significant aging effects on priming subdominant M2e and HA stalk IgG antibody responses. This study demonstrates that a heterologous prime-boost strategy with recombinant influenza virus expressing extra M2e epitopes provides more effective cross protection than homologous vaccination.

Keywords: Cross protection; Live attenuated virus; M2e; Recombinant influenza virus.
 
Back
Top Bottom